Results of whole abdominopelvic irradiation with nodal boost for patients with endometrial cancer at high risk of failure in the peritoneal cavity. A prospective clinical trial at the Mayo Clinic.
From August 1981 to December 1986, 47 patients with endometrial cancer, surgical stage I through IV, received adjuvant whole abdominopelvic irradiation with a nodal and vaginal boost. Median age was 66.5 years (range: 37 to 86 years). Twenty-two patients were stages I-II and 25 patients were stages III-IV. Thirty-four patients (79 per cent) had positive peritoneal cytology, 29 patients (62 per cent) had deep myometrial involvement, 27 patients (58 per cent) had high-grade lesions, 18 patients (40 per cent) had either serous-papillary or adenosquamous histologic variants, and 10 patients (22 per cent) had residual disease of up to 2 cm remaining after operation, mostly in the form of nodal disease. Twenty-four patients (51 per cent) have had two or more laparotomies. Mean follow-up was 40.5 months (range: 17 to 81 months). The 5-year overall survival rate was 66 per cent, and the 5-year relapse-free survival rate was 77 per cent. Toxicity has been modest, usually of the acute type, and particularly evident in thin patients (weight below 115 pounds).
D000005:Abdomen; D000230:Adenocarcinoma / Q000473:pathology / Q000532:radiotherapy; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015182:Lymphatic Irradiation; D008875:Middle Aged; D008910:Minnesota; D009361:Neoplasm Invasiveness; D010388:Pelvis; D010534:Peritoneal Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000556:secondary*; D011446:Prospective Studies; D011878:Radiotherapy / Q000009:adverse effects; D012307:Risk Factors; D014594:Uterine Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery